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Many agents constrict isolated afferent arterioles only at
concentrations higher than their physiological levels. Here
we determined if norepinephrine, as released by sympathetic
nerve activity, could influence the angiotensin II
responsiveness of isolated mouse afferent arterioles.
Pretreatment of the arterioles for short periods with
norepinephrine significantly increased the ability of 10
picomolar angiotensin II to constrict the vessels, an effect
inhibited by the alpha receptor blockers prazosin (a-1) or
yohimbine (a-2). Although the intracellular calcium transients
induced by angiotensin were not different, phosphorylation
of the 20kDa myosin light chain was significantly increased
in the presence of norepinephrine. Phosphorylation of the
p38 mitogen-activated protein kinase was not changed.
Phosphorylation of the myosin phosphatase targeting
subunit at Thr696, but not at Thr850, was significantly
enhanced by, norepinephrine pretreatment, thus increasing
the calcium sensitivity of the arteriolar smooth muscle. Our
results show that norepinephrine increases afferent arteriolar
sensitivity to angiotensin II by means of alpha receptor
activation, causing increased calcium sensitivity through
phosphorylation of the myosin phosphatase targeting
subunit.
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Afferent arterioles are important in the regulation of renal
blood flow as they are the point of preglomerular resistance
that produces the largest change in resistance, for example,
with angiotensin II (Ang II) or norepinephrine (NE)
stimulation.1 The tone of the afferent arteriole is determined
by endocrine and paracrine factors, as well as by sympathetic
nerve activity2 and autoregulation.3 The aim of this study was
to investigate whether NE, as released by sympathetic nerves,
can augment vasoconstriction caused by Ang II in isolated
renal afferent arterioles from mice. This may be a mechanism
by which sympathetic activation may enable afferent
arteriolar control by Ang II, even at physiological Ang II
concentrations. We further identify the main signaling
pathways responsible for the effect of NE on Ang II-induced
contraction.
On rabbit and mouse afferent arterioles, NE causes a
constriction, primarily by activating a-1 adrenoceptors.4,5
a-2 receptors contribute to a lesser extent to NE-induced
constriction.5 Ang II causes the afferent arteriole to constrict
in a concentration-dependent manner,4 which is mediated
primarily by the AT1a receptor in the rat.6
The interaction between Ang II and NE has been studied
in vivo7–9 and long-term Ang II infusion has been shown to
affect afferent arteriolar sensitivity to NE.10,11 Such an
interaction may have a role in different physiological and
pathophysiological situations, in which the sympathetic
and/or the renin–angiotensin system is activated. However,
the NE–Ang II interactions on the afferent arteriole remain to
be determined. In this context, the role of intracellular
calcium signaling is yet unknown, and our understanding
of the activation pathways for contractile proteins in renal
resistance vessels remains scant with regard to Ang II and NE
and their potential interaction.
The contraction of smooth muscle is regulated by the
phosphorylation and dephosphorylation of the 20 kDa
myosin light chain (MLC(20)).12 MLC(20) is phosphorylated
by MLC kinase, which is activated through increased
cytosolic calcium concentrations. Dephosphorylation of
MLC(20) is mediated by MLC phosphatase (MLCP).12
MLCP activity is modulated by phosphorylation of the
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myosin phosphatase-targeting subunit at Thr696 or Thr850,
which inhibits MLCP binding to MLC(20).13 Interestingly,
NE can cause phosphorylation of both the Thr696 and
Thr850 sites, which may increase the calcium sensitivity of
the smooth muscle.14–16 Another possible pathway for
increasing calcium sensitivity is the p38-mitogen-activated
kinase (p38-MAPK), which has been shown to induce
MLC(20) phosphorylation and constriction at low calcium
concentrations,17,18 potentially independent of calcium
transients.19 Both Ang II and NE can induce p38-MAPK
phosphorylation,20,21 which may thereby contribute to an
interaction between NE and Ang II.
The aim of this study was to investigate whether NE
stimulation affects the reaction of isolated mouse afferent
arterioles to Ang II through its a-receptors. Furthermore, we
wanted to show whether this is mediated through increased
calcium signaling or increased calcium sensitivity as dis-
cussed above.
RESULTS
NE treatment enhances the effect of Ang II
Before NE treatment, the vessel diameter was 8.65±0.72 mm.
NE treatment caused a sustained constriction to
0.08±0.06 mm and the vessels returned to the basal diameter
after washout (8.55±0.46 mm). Ang II does not constrict
the afferent arteriole at 1010mol/l or at lower concen-
trations. The maximal constriction caused by Ang II was
by 36.6±5.8%, which was reached at 108mol/l
(Figure 1a and b). Vessels treated with NE showed a
constriction already at 1011mol/l (46.3±15.8% reduction
of the diameter compared with 4.4±4.3% in nontreated
vessels, Po0.05). The constriction was also stronger than that
seen in control vessels at 1010 and 109mol/l Ang II (Figure
1a and b).
Calcium transients were not increased by treatment with
both NE and Ang II
Cytosolic calcium transients were measured after an applica-
tion of 1011mol/l Ang II in control vessels (n¼ 4) and in
vessels treated with 104mol/l NE (n¼ 5, Figure 2). NE
treatment by itself caused a 135.6±15 nM peak calcium
increase. The baseline was 177.5±13.9 nM Ca2þ before and
190.3±24.2 nM Ca2þ after washout of NE. The baseline was
similar in control vessels (181.7±23.6 nM Ca2þ ). Remark-
ably, there was no difference between the maximal calcium
response to Ang II in control vessels (29.4±7.1 nM Ca2þ )
and that in NE-treated vessels (31.5±13.3 nM Ca2þ ).
Both a-1 and a-2 receptors are necessary for the effect of NE
on Ang II
Both prazosin and yohimbine inhibit the effect of NE on the
dose–response of afferent arteriole to Ang II (Figure 3a and b).
The curves are similar to the normal Ang II curve while being
different from the Ang II dose–response curve in NE-treated
vessels (Po0.05 by two-way analysis of variance).
Myosin phosphatase-targeting subunit phosphorylation was
enhanced by NE and Ang II together
Norepinephrine alone caused an increase in the phosphor-
ylation of myosin phosphatase-targeting subunit at thr696,
which remained after washout (0.85±0.14 to 1.4±0.5,
Po0.05). Ang II 1011mol/l did not enhance myosin
phosphatase-targeting subunit phosphorylation, but the
combination of 1011mol/l Ang II with NE treatment
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Figure 1 | Effect of norepinephrine on angiotensin II–mediated constriction. (a) A strong leftward and downward shift of the
dose–response curve of the afferent arteriolar diameter to Ang II after treatment with norepinephrine (NE). The normal Ang II dose–response
is shown as filled squares (N¼ 6), NE-treated vessels are shown as filled triangles (n¼ 5). (b) The same data as percentages. *Denotes a
significant difference between nontreated and treated vessels by Tukey-HSD test (Po0.05).
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showed a phosphorylation similar to that of NE alone
(1.24±0.38, Po0.05 compared with control Figure 4a). The
combination of NE treatment with 1011mol/l of Ang II did
not change myosin phosphatase-targeting subunit thr850
phosphorylation. No other treatment caused any significant
effect on the thr850 phosphorylation of myosin phosphatase-
targeting subunit as seen in Figure 4b.
p38-MAPK phosphorylation was reduced by the combination
of NE and Ang II
Norepinephrine by itself increased p38-MAPK to 0.75±0.23
compared with the 0.29±0.12 of baseline. Ang II did not
affect p38-MAPK phosphorylation by itself (0.55±0.29 for
1011mol/l Ang II), but in combination with NE, a
concentration of 1011mol/l Ang II inhibited the increase
in phosphorylation caused by NE (0.27±0.09, Figure 4c).
Myosin light chain phosphorylation was increased by NE and
Ang II together
Norepinephrine strongly increased MLC(20) phosphoryla-
tion (0.96±0.5–2.9±0.67, Po0.05), whereas Ang II did not
affect MLC(20) phosphorylation significantly (1.3±0.57 at
1011mol/l and 1.22±0.36 at 108mol/l Ang II, respectively)
with the protocols used in this study. The combination of NE
pretreatment with low-dose Ang II did not increase MLC(20)
phosphorylation above that of NE treatment alone, but it was
significantly higher than the baseline phosphorylation
(1.81±0.18, Po0.05, Figure 4d).
DISCUSSION
The main finding presented in this paper is the greatly
enhanced response to Ang II in the afferent arteriole after
transient treatment with NE (2min, followed by 10min
washout). This effect of NE seems to be dependent on both
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Figure 2 | Intracellular calcium measured as Fura-2 340/380
ratio in perfused afferent arterioles. White bars show baseline
before norepinephrine (NE) treatment and the maximum calcium
concentration measured for 2min after application of either NE
(light gray), Ang II (gray), or NE and Ang II (black). *Denotes a
significant difference, Po0.05, compared with that of the
corresponding baseline.
Af
fe
re
n
t a
rte
rio
la
r d
ia
m
et
er
 (μ
m
)
Pe
rc
e
n
ta
ge
 d
ia
m
et
er
 c
ha
ng
e
12
10
8
6
4
2
0
–14 –12 –10 –8 –6
log (Ang II) mol/l
Ang II after 10–4 mol/l NE
10–4 mol/l NE and yohimbine
10–4 mol/l NE and prazosin
0
–20
–40
–60
–80
–14 –12 –10 –8 –6
log (Ang II) mol/l
∗
†
∗
†
∗
†
Figure 3 | The a-1 antagonist prazosin and a-2 antagonist yohimbine inhibition of the 104mol/l norepinephrine (NE) effect on
Ang II-elicited constriction (shown in Figure 1 as well). (a) Prazosin is depicted as solid circles (n¼ 6), yohimbine as solid squares (n¼ 7).
(b) The same data shown as percentages. *Denotes a significant difference between yohimbine and NE-treated vessels and NE-treated
vessels (solid circles in Figure 1b). wDenotes a difference between prazosin and NE-treated vessels and NE-treated vessels by
Tukey-HSD test (Po0.05) (solid triangles).
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a-1 and a-2 receptors, but does not involve calcium
signaling. Rather it involves a phosphorylation-dependent
inactivation of the myosin phosphatase-targeting subunit of
MLC phosphatase. This goes along with a significant increase
in the phosphorylation of the 20 kDa MLC.
Interaction of Ang II and NE, that is, of the renin–angio-
tensin system and the sympathetic nervous system, has been
shown in in vivo studies in the rat.7–9 Interrupting the
sympathetic nervous system decreased the effect of Ang II on
renal blood flow, whereas inhibition of Ang II blunted the
effect of renal sympathetic nerve stimulation.22 It has been
indicated that a-1 receptors contribute to the vasoconstric-
tive effect of infused Ang II,23 and a dual knockout of the
AT1a and AT1b Ang II receptors has been shown to decrease
the effects of NE.24 In this study, a-1 as well as a-2 blockade
can inhibit the effect of transient NE application on Ang II
response in mice. Such a cooperative action of both
a-receptor types was also shown for the enhancing effect of
adenosine triphosphate on NE-induced constrictions,5 and
may indicate that a-receptors are to some degree physically
associated in the plasma membrane.
Cytosolic calcium changes did not differ between treated
and nontreated arterioles. The fact that we show relatively
small calcium transients at concentrations in which we
have considerable constriction (NE followed by Ang II
1011mol/l) indicates that calcium sensitization may be an
important mechanism for the effect of NE.
The myosin phosphatase-targeting subunit showed differ-
ential phosphorylation states at the known sites, Thr696 and
Thr850, in response to NE, Ang II, and their combination.
This study demonstrates an increase in the phosphorylation
of Thr696 in response to NE and Ang II. It seems that this NE
effect contributes to the enhanced phosphorylation after
combined NE and Ang II treatment than the Ang II
application alone. A known pathway for changing calcium
sensitivity is through the MLCP that dephosphorylates
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Figure 4 |Western blot results for phosphorylated proteins. (a) Myosin phosphatase-targeting subunit phosphorylation at thr-696.
(b) Myosin phosphatase-targeting subunit phosphorylation at thr-850. (c) p38-MAPK phosphorylation. (d) MLC(20) phosphorylation at
ser-20. Relative a-actin levels served as a loading control. *Denotes a significant difference compared with control, n¼ 10 isolated afferent
arterioles for each group. (e) Representative western blots were created by pooling the protein extracts from 10 vessels per group,
indicating the phosphorylation status of myosin phosphatase-targeting subunit (MYPT-1) at thr-696 or thr-850, p38-MAPK, and MLC(20)
after NE (104mol/l), Ang II (1011) or the combined treatment of both substances. Relative a-actin levels were used to normalize results.
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MLC(20) and reduces the contractile force. The myosin
phosphatase-targeting subunit is necessary for MLCP binding
to MLC(20) and phosphorylation of Thr696, as shown here,
inhibits MLC(20) binding and reduces dephosphorylation,
causing a net increase in the phosphorylation rate of
MLC(20).25 Thus, the enhanced phosphorylation of myosin
phosphatase-targeting subunit at Thr696 may contribute to
an increased MLC(20) phosphorylation by inhibition of
MLCP.14
The fact that activation of both receptors is necessary and
that the a-1, G(q)-associated,26 signaling pathway and the
a-2, G(i)27 pathway converge on phospholipase C activation
may indicate that the difference lies upstream of the
activation of phospholipase C, that is, on the level of
G-proteins or direct receptor interactions. However, the
convergent phospholipase C activation has been shown to be
important by itself in the interaction between Ang II-induced
AT1 activation and NE-induced a-2 activation in the rat
during simultaneous stimulation.28 On the other hand,
repeated treatment with Ang II does not lead to sensitization,
but rather to a decreased reactivity,29 which is also observed
in our results.17 Repeated applications of NE do not change
the reaction from one application to the next,29 which is
consistent with our observations in the mouse (Hultstro¨m
M., unpublished observation). Taken together, this indicates
that there is some effect beyond calcium sensitization that
makes the mechanism specific to the interaction between NE
and Ang II.
In these studies, vessels are treated with a very high
concentration of NE. The results may be directly applicable
only to situations with a very strong sympathetic activity,
such as hemorrhagic shock, in which it may be important.
However, the mechanism described could well have a role in
other situations with an increased renal sympathetic nerve
activity, such as hypertension and edema in heart failure and
nephrotic syndrome.30 This is an area that warrants further
investigation.
In conclusion, after NE treatment, there is a stronger
vasoconstrictor response of the afferent arteriole to low
concentrations of Ang II. This provides a mechanism by
which physiological concentrations of Ang II may affect renal
circulation. Second, the apparent dependence on both a-1
and a-2 receptors suggests a closer relationship between these
or their respective G-proteins in the interaction with other
transmitter systems. Finally, the lasting effect after washout of
NE indicates a change in the contractile machinery, which
increases the sensitivity of the afferent arteriole for longer
times; this seems to be an effect of phosphorylation of the
myosin phosphatase-targeting subunit.
MATERIALS AND METHODS
Animals
Male mice of the C57 black 6J strain (Scanbur BK AB, Solna,
Sweden) were used in these experiments. The mice weighed between
25 and 30 g. The animals were fed standard pelleted food (Scanbur
BK AB, Solna, Sweden) and had free access to tap water. The
experiments were approved for ethics by the board of animal
experiments at the county court of Uppsala.
Dissection and perfusion
Dissection and perfusion were performed as previously published.31
In short, the animals were killed by cervical dislocation and kidneys
were removed and immediately placed in ice-cold Dulbecco’s
modified Eagle’s medium with 0.1% albumin. The kidneys were
sliced into thin transversal sections and afferent arterioles were
dissected using sharpened forceps (no. 5, Dumont) under a
stereomicroscope (Leica Microsystems GmbH, Wetzlar, Germany).
Arterioles from the outer cortex with attached glomeruli were
selected and transferred to a thermoregulated chamber on the stage
of an inverted microscope (Noran, Middleton, WI, USA). Glass
pipettes (Drummond Scientific Company, Broomall, PA, USA)
mounted in a perfusion system (Vestavia Scientific, Vestavia Hills,
AL, USA) were used to fix and perfuse the arteriole and glomerulus.
The holding pipette (outer diameter (OD) 2.13mm, inner diameter
(ID) 1.63mm) had an aperture of roughly 26 mm at the tip and a
constriction of about 20 mm after customizing. The proximal end of
the arteriole was aspirated into this pipette. The inner, perfusion
pipette (OD 1.19mm, ID 1.02mm), with a diameter of the tip of
5 mm, was advanced into the lumen of the arteriole. This pipette was
connected to a reservoir containing the perfusion solution and to a
manometer. The arterioles were perfused at 371C with a pressure of
100mmHg in the pressure head, which, as previously shown,
produces a perfusion pressure within the autoregulatory range and
with a physiological perfusion flow rate.31 Arterioles that exhibited a
basal tone and clear lumen were tested for viability by changing the
bath solution to 100mmol/l KCl, after which the arterioles were
allowed to recover for 10min. Only arterioles showing a strong
constriction to the KCl challenge were used.
Measurement of arteriolar diameter
These experiments were recorded on super video home system
videotapes (video recorder Panasonic NV-HS830, Matsushita
Audio Video GmbH, Lueneburg, Germany). The final magnification
results from a Nikon  60/1.2 water-immersion objective lens
and projection ( 1) were obtained using a 0.300 chip digital camera
(VCAM110; Phytec Technology Holding AG, Mainz, Germany).
Video sequences were digitized using a frame grabber card
(pciGrabber-4plus; Phytec Technologie Holding AG). Vessel
diameters were determined using customized software
(Dr H. Siegmund, Johannes-Mu¨ller-Institute of Physiology,
Humboldt-University of Berlin, Germany). The equipment allowed
a resolution of 0.11 mm of the vessel structure. The luminal diameter
of the afferent arteriole was measured at one point in five
consecutive pictures with 1-s intervals during the last 10–15 s of
each 2-min treatment period. Each vessel was used for one
experiment only. Control diameter was obtained after recovery
from the KCl test, shortly before starting the experimental protocol.
Measurement of intracellular calcium
In separate experiments, afferent arterioles were dissected and
perfused as described above and incubated with Fura-2 AM (VWR
International AB, Stockholm, Sweden) at 105mol/l for 45min. The
arterioles were excited alternately at 340 and 380 nm and emission
was measured at 510 nm, with 3-s collection periods for each
excitation. The ratio between emissions in successive time periods
(340/380 nm) was used to determine intracellular calcium concen-
tration against a calibrated standard (Fura-2 Calcium Imaging
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Calibration Kit from Molecular Probes, F-6774, Carlsbad, CA, USA)
in the same microscope. Fluorescence was detected using Applied
Imaging Quanticell-900 (VisiTech International, Sunderland, UK).
Three regions of interest were selected on each vessel, one covering
the whole width of the vessel and one from each side of the vessel
wall. The tracings from these areas were generally very similar.
Results from the three areas were averaged for each vessel. Fura-2
ratio was measured for 2min after application of Ang II. Calcium
increase was calculated as the maximum recorded after application
minus the baseline directly before application of Ang II.
Diameter dose–response curves
A normal dose–response curve for Ang II was obtained by
exchanging the bath solution at 2-min intervals in steps of 10 times
the dilution from 1014 to 106mol/l. Vessel diameter was measured
during the last 10–15 s of each period as a measure of sustained
vessel diameter change. Only one experimental protocol for
measurement of constriction and calcium transient each (agonists
alone, in combination or together with antagonists) was performed
in each arteriole.
NE treatment
To study the interaction of NE and Ang II on the constriction of
afferent arterioles, we incubated the isolated perfused arterioles with
104mol/l NE for 2min, followed by a 10-min washout period
before performing an Ang II dose–response curve as described
above.
Use of inhibitors
All antagonists were purchased from Sigma Chemicals (St Louis,
MO, USA). While investigating the effects of specific receptor
blockers on the interaction between NE and Ang II, the receptor
antagonists were added together with NE. Both NE and the
antagonist were washed out before investigating the dose–response
for Ang II. The receptor antagonists used were a-1-adrenoceptor
blocker prazosin at a concentration of 107mol/l and a-2-
adrenoceptor blocker yohimbine at a concentration of 107mol/l.
We have used these concentrations previously.5 Prazosin at a
concentration of 107mol/l blunted the constriction caused by
104mol/l NE to approximately half, whereas yohimbine did not
affect constriction, but inhibited the interaction of ATP with NE,
although others have shown that 107mol/l prazosin does not
abolish the effect of yohimbine in mice.32
Western blot
Cellular extracts from preglomerular vessels were prepared as
described by Lai et al.17 The isolated renal resistance vessels were
treated with 104mol/l NE or with Ang II at 1011mol/l, followed
by a washout, or a combination of NE treatment and washout of NE
(10min) and subsequent treatment with Ang II (1011mol/l),
followed by washout. Protein extracts were separated by SDS–poly-
acrylamide gel electrophoresis and transferred to HybondTM-P
membranes (GE Healthcare Europe, GmbH). The following
phosphorylation-specific antibodies were used for detection of the
protein phosphorylation status: anti-Myosine regulatory light chain
(pSer20) antibody (Acris antibodies GmbH, Herford, Germany,
R1535P), anti-phos p38-MAPK antibody (Calbiochem, no. 506119),
anti-phosphorylated myosin phosphatase-targeting subunit at
thr696 (Millipore, Schwalbach/Ts., Germany, no. 07-251), anti-
phosphorylated myosin phosphatase-targeting subunit at thr850
(Millipore, no. 36-003). Membranes were stripped for 5min with
distilled water, for 5–15min with 0.2 M NaOH, and again for 5min
with distilled water, and reprobed using an anti-a-actin antibody
(Acris antibodies GmbH, AB5694). Detection of relative smooth
muscle-specific a-actin levels served as loading control.
Statistics
Functions were analyzed with two-way analysis of variance to test
for constriction over time and for difference between curves.
Baseline diameter varies between the different groups of vessels
used for diameter measurement. In particular, the prazosin-treated
group seems to have a lower baseline diameter, and has a borderline
significant difference than the others by analysis of variance.
Although this is a notable difference, we do not believe that these
vessels belong to any special population, but that what we see is an
effect of the natural variation in diameters of afferent arterioles in
mice. The reactivity of afferent arterioles from mice seems to be very
consistent and not related to baseline diameter when studied as
relative changes, which therefore forms the basis of our statistics and
discussion.
Tukey-HSD test was used as a post hoc test between curves and
t-tests were used to test for significant difference in calcium increase.
Po0.05 was considered to be significant. Statistics were calculated
using R 2.8.0 software (Vienna, Austria).33
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